Alzheimer's disease (AD) is a progressive neurodegenerative disorder accounting for 60-80% of dementia cases. For many years, AD causality was attributed to amyloid-β (Aβ) aggregated species. Recently, multiple therapies that target Aβ aggregation have failed in clinical trials, since Aβ aggregation is found in AD and healthy patients. Attention has therefore shifted toward the aggregation of the tau protein as a major driver of AD. Numerous inhibitors of tau-based pathology have recently been developed. Diagnosis of AD has shifted from measuring late stage senile plaques to early stage biomarkers, amyloid-β and tau monomers and oligomeric assemblies. Synthetic peptides and some derivative structures are being explored for use as theranostic tools as they possess the capacity both to bind the biomarkers and to inhibit their pathological self-assembly. Several studies have demonstrated that O-linked glycoside addition can significantly alter amyloid aggregation kinetics. Furthermore, natural O-glycosylation of amyloid-forming proteins, including amyloid precursor protein (APP), tau, and α-synuclein, promotes alternative nonamyloidogenic processing pathways. As such, glycopeptides and related peptidomimetics are being investigated within the AD field. Here we review advancements made in the last 5 years, as well as the arrival of sugar-based derivatives.
Dynamin is a GTPase that plays a vital role in clathrin-dependent endocytosis and other vesicular trafficking processes by acting as a pair of molecular scissors for newly formed vesicles originating from the plasma membrane. Dynamins and related proteins are important components for the cleavage of clathrin-coated vesicles, phagosomes, and mitochondria. These proteins help in organelle division, viral resistance, and mitochondrial fusion/fission. Dysfunction and mutations in dynamin have been implicated in the pathophysiology of various disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Charcot-Marie-Tooth disease, heart failure, schizophrenia, epilepsy, cancer, dominant optic atrophy, osteoporosis, and Down's syndrome. This review is an attempt to illustrate the dynamin-related mechanisms involved in the above-mentioned disorders and to help medicinal chemists to design novel dynamin ligands, which could be useful in the treatment of dynamin-related disorders.
It is estimated that the human genome encodes 15% of proteins that are considered to be disease-modifying. Only 2% of these proteins possess a druggable site that the approved clinical candidates target. Due to this disparity, there is an immense need to develop therapeutics that may better mitigate the disease or disorders aroused by non-druggable and druggable proteins or enzymes. The recent surge in approved oligonucleotide therapeutics (OT) indicates the imminent potential of these therapies. Oligonucleotide-based therapeutics are of intermediate size with much-improved selectivity towards the target and fewer off-target effects than small molecules. The OTs include Antisense RNAs, MicroRNA (MIR), small interfering RNA (siRNA), and aptamers, which are currently being explored for their use in neurodegenerative disorders, cancer, and even orphan diseases. The present review is a congregated effort to present the past and present of OTs and the current efforts to make OTs for plausible future therapeutics. The review provides updated literature on the challenges and bottlenecks of OT and recent advancements in OT drug delivery. Further, this review deliberates on a newly emerging approach to personalized treatment for patients with rare and fatal diseases with OT.
The antioxidant properties of methanol extracts of 12 Indian medicinal plants, traditionally used in disease areas that probably involve free radical mechanisms, were evaluated by two methods, namely the DPPH (1,1-diphenyl-2-picryl hydrazyl) test and the lipid peroxidation assay. In the latter assay, seven of these extracts showed 90% or more activity compared with the standard, vitamin E and hence were studied in detail after the removal of interfering pigments. The selective pigment removal from the extracts led to an increase in free radical scavenging activity and a decrease in inhibition of lipid peroxidation.
:
Glycogen Synthase Kinase 3 (GSK3) is one of the Serine/Threonine protein kinases that has gained a lot of
attention for its role in a variety of pathways. It has two isoforms, GSK3α and GSK3β. However, GSK3β is
highly expressed in different areas of the brain and has been implicated in Alzheimer’s disease as it is involved
in tau phosphorylation. Due to its high specificity concerning substrate recognition, GSK3 has been considered
as an important target. In the last decade, several GSK3 inhibitors have been reported and two molecules are in
clinical trials. This review collates the information published in the last decade about the role of GSK3 in
Alzheimer’s disease and progress in the development of its inhibitors. Using this collated information, medicinal
chemists can strategize and design novel GSK3 inhibitors that could be useful in the treatment of Alzheimer’s
disease.
Astrocytes, the star shaped glial cells, are known to possess supportive and homeostatic role for the neurons. Recently, reactive gliosis, which involves alterations in functioning and phenotype of different glial cells, has been implicated in Alzheimer's Disease (AD). Studies have revealed that astrocyte response to gross tissue damaging injury leads to anisomorphic astrogliosis reinforcing a cascade of events, eventually increasing the pathogenesis of AD and many other neurodegenerative disorders. This review presents the involvement of reactive astrocytes in reduced Aβ clearance and in neuro-neglect hypothesis. Understanding of reactivity and fundamental biology of astrocytes may open new avenues of alternative treatments and therapeutic strategies targeting astrocytes and related events for the treatment of AD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.